Abstract
Recently, we disclosed a series of potent pyrimidine benzamide-based thrombopoietin receptor agonists. Unfortunately, the structural features required for the desired activity conferred physicochemical properties that were not favorable for the development of an oral agent. The physical properties of the series were improved by replacing the aminopyrimidinyl group with a piperidine-4-carboxylic acid moiety. The resulting compounds possessed favorable in vivo pharmacokinetic properties, including good bioavailability.
MeSH terms
-
Administration, Oral
-
Animals
-
Benzoates / administration & dosage
-
Benzoates / chemistry*
-
Benzoates / metabolism*
-
Biological Availability
-
Caco-2 Cells
-
Humans
-
Hydrazines / administration & dosage
-
Hydrazines / chemistry*
-
Hydrazines / metabolism*
-
Piperidines / chemical synthesis
-
Piperidines / metabolism
-
Pyrazinamide / analogs & derivatives
-
Pyrazinamide / chemical synthesis
-
Pyrazinamide / metabolism
-
Pyrazoles / administration & dosage
-
Pyrazoles / chemistry*
-
Pyrazoles / metabolism*
-
Pyrimidines / chemical synthesis
-
Pyrimidines / metabolism
-
Rats
-
Receptors, Thrombopoietin / agonists*
-
Receptors, Thrombopoietin / metabolism*
Substances
-
Benzoates
-
Hydrazines
-
Piperidines
-
Pyrazoles
-
Pyrimidines
-
Receptors, Thrombopoietin
-
Pyrazinamide
-
pyrazinoic acid
-
piperidine
-
pyrimidine
-
eltrombopag